%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
2013-09-17T11:41:41+02:00
2013-09-17T11:41:41+02:00
2013-09-17T11:41:41+02:00
Adobe Acrobat 10.0
application/pdf
EACS 2013
uuid:45a10b00-3a24-4805-b7b6-e00d54ac6db6
uuid:0a61667e-147d-48fe-9aec-caa5a70d2c96
Acrobat Web Capture 10.0
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
11 0 obj
<>stream
/CS0 cs 1 scn
57 176.712 480.75 651.135 re
f
62.068 759.44 475.682 63.34 re
f
q
62.068 759.44 475.682 63.34 re
W n
q
/GS0 gs
475.6827906 0 0 -63.3399189 62.0671935 822.7796119 cm
/Im0 Do
Q
Q
62.068 752.472 475.682 6.968 re
f
62.068 755.639 475.682 0.634 re
f
0.604 scn
q 1 0 0 1 62.0676 756.2727 cm
0 0 m
0.633 -0.634 l
475.049 -0.634 l
475.682 0 l
h
f
Q
0.933 scn
q 1 0 0 1 62.0676 755.6391 cm
0 0 m
0.633 0 l
475.049 0 l
475.682 0 l
h
f
Q
0.604 scn
q 1 0 0 1 62.0676 755.6391 cm
0 0 m
0.633 0 l
0 0.634 l
h
f
Q
0.933 scn
q 1 0 0 1 537.1164 755.6391 cm
0 0 m
0.634 0 l
0.634 0.634 l
h
f
Q
1 scn
62.068 722.069 475.682 30.403 re
f
62.068 685.966 475.682 36.104 re
f
62.068 615.025 475.682 70.941 re
f
62.068 405.37 475.682 209.655 re
f
62.068 334.429 475.682 70.941 re
f
62.068 337.595 475.682 0.634 re
f
0.604 scn
q 1 0 0 1 62.0676 338.229 cm
0 0 m
0.633 -0.634 l
475.049 -0.634 l
475.682 0 l
h
f
Q
0.933 scn
q 1 0 0 1 62.0676 337.5954 cm
0 0 m
0.633 0 l
475.049 0 l
475.682 0 l
h
f
Q
0.604 scn
q 1 0 0 1 62.0676 337.5954 cm
0 0 m
0.633 0 l
0 0.634 l
h
f
Q
0.933 scn
q 1 0 0 1 537.1164 337.5954 cm
0 0 m
0.634 0 l
0.634 0.634 l
h
f
Q
BT
0 scn
/TT0 1 Tf
0.03 Tw 8.2342 0 0 8.2342 62.0672 734.7371 Tm
[(Poster)-33( Exhibition)-50( Presentation)]TJ
/TT1 1 Tf
-0.028 Tw 10.1344 0 0 10.1344 62.0672 712.5682 Tm
[(PE21/18)-39( -)-42( Late)-6( Presenters)-18( and)-34( Significance)-46( of)-56( Screening)-40( Tests)-13( in)-48( Early)-54( Diagnosis)-33( of)-56( HIV)-20( Infection)]TJ
0 -1.187 TD
[(in)-48( Istanbul,)-13( Turkey:)-13( Data)-20( from)-28( ACTHIV)-28(-)-42(IST)-6( Study)-34( Group)]TJ
/TT0 1 Tf
0 Tw ( )Tj
/TT2 1 Tf
/Span<>> BDC
T*
( )Tj
EMC
/TT0 1 Tf
0.03 Tw 8.2342 0 0 8.2342 62.0672 675.831 Tm
[(H. Kumbasar)-58( Karaosmanoglu)]TJ
ET
/CS0 CS 0 SCN
0.633 w
q 1 0 0 1 62.0672 675.1976 cm
0 0 m
109.578 0 l
S
Q
BT
/TT0 1 Tf
0 Tw 6.9674 0 0 6.9674 171.6452 678.998 Tm
(1)Tj
0.03 Tw 8.2342 0 0 8.2342 176.079 675.831 Tm
[(,)-30( B.)-55( Mete)]TJ
0 Tw 6.9674 0 0 6.9674 210.2826 678.998 Tm
(2)Tj
0.03 Tw 8.2342 0 0 8.2342 214.7164 675.831 Tm
[(,)-30( G.)-21( Alper)]TJ
0 Tw 6.9674 0 0 6.9674 250.8201 678.998 Tm
(3)Tj
0.03 Tw 8.2342 0 0 8.2342 255.254 675.831 Tm
[(,)-30( F.)-34( Sargin)]TJ
0 Tw 6.9674 0 0 6.9674 294.5247 678.998 Tm
(4)Tj
0.03 Tw 8.2342 0 0 8.2342 298.9585 675.831 Tm
[(,)-30( B.)-55( Ceylan)]TJ
0 Tw 6.9674 0 0 6.9674 340.7628 678.998 Tm
(5)Tj
0.03 Tw 8.2342 0 0 8.2342 345.1966 675.831 Tm
[(,)-30( O.)-21( Altuntas)-2( Aydin)]TJ
0 Tw 6.9674 0 0 6.9674 414.8705 678.998 Tm
(1)Tj
0.03 Tw 8.2342 0 0 8.2342 419.3043 675.831 Tm
[(,)-30( M.)-43( Yemisen)]TJ
0 Tw 6.9674 0 0 6.9674 468.7095 678.998 Tm
(2)Tj
0.03 Tw 8.2342 0 0 8.2342 473.1433 675.831 Tm
[(,)-30( D. Yildiz)]TJ
0 Tw 6.9674 0 0 6.9674 509.247 678.998 Tm
(3)Tj
0.03 Tw 8.2342 0 0 8.2342 513.6808 675.831 Tm
[(,)-30( N.)]TJ
0 Tw -54.846 -1.538 Td
(Ozgunes)Tj
6.9674 0 0 6.9674 95.6374 666.33 Tm
(4)Tj
0.03 Tw 8.2342 0 0 8.2342 100.0711 663.163 Tm
[(,)-30( R. Ozaras)]TJ
0 Tw 6.9674 0 0 6.9674 142.5089 666.33 Tm
(2)Tj
0.03 Tw 8.2342 0 0 8.2342 146.9427 663.163 Tm
[(,)-30( F.)-34( Tabak)]TJ
0 Tw 6.9674 0 0 6.9674 185.58 666.33 Tm
(2)Tj
0.03 Tw 8.2342 0 0 8.2342 190.0138 663.163 Tm
[(,)-30( ACTHIV)-25(-)-52(IST)-59( Study)-58( Group)]TJ
/Span<>> BDC
12.385 0 Td
( )Tj
EMC
/TT3 1 Tf
0 Tw 6.9674 0 0 6.9674 62.0672 653.662 Tm
(1)Tj
0.03 Tw 8.2342 0 0 8.2342 66.501 650.4951 Tm
[(Haseki)-21( Education)-15( and)-24( Research)-29( Hospital,)-33( Istanbul,)-66( Turkey,)-51( )]TJ
0 Tw 6.9674 0 0 6.9674 287.5573 653.662 Tm
(2)Tj
0.03 Tw 8.2342 0 0 8.2342 291.9911 650.4951 Tm
[(IU,)-30( Cerrahpasa)-7( Medical)-16( School,)-50( Istanbul,)-66( Turkey,)-51( )]TJ
0 Tw 6.9674 0 0 6.9674 476.9437 653.662 Tm
(3)Tj
0.03 Tw 8.2342 0 0 8.2342 481.3774 650.4951 Tm
[(Sisli)-13( Education)]TJ
-50.923 -1.538 Td
[(and)-24( Research)-29( Hospital,)-33( Istanbul,)-66( Turkey,)-51( )]TJ
0 Tw 6.9674 0 0 6.9674 215.9832 640.994 Tm
(4)Tj
0.03 Tw 8.2342 0 0 8.2342 220.417 637.827 Tm
[(Goztepe)-66( Education)-15( and)-24( Research)-29( Hospital,)-33( Istanbul,)-66( Turkey,)-51( )]TJ
0 Tw 6.9674 0 0 6.9674 447.8073 640.994 Tm
(5)Tj
0.03 Tw 8.2342 0 0 8.2342 452.2411 637.827 Tm
[(Bezmialem)-55( Vakif)]TJ
-47.385 -1.231 Td
[(University,)-25( Faculty)-8( of)-12( Medicine,)-29( Istanbul,)-66( Turkey)]TJ
/TT1 1 Tf
0 Tw 0 -2.462 TD
[(Objectives:)-70( )]TJ
/TT0 1 Tf
0.03 Tw 5.769 0 Td
[(The)-46( aim)-4( of)-12( this)-59( study)-72( was)-68( to)-12( determine)-15( the)-71( frequency)-70( of)-12( late)-3( HIV)-25( presenters)-45( and)-24( the)-71( potential)-66( of)-12( screening)-50( tests)]TJ
-5.769 -1.231 Td
[(for)-64( an)-42( early)-64( diagnosis)-7( of)-12( HIV)-25( infection)-45( in)-68( the)-72( ACTHIV)-25(-)-52(IST)-59( \(ACTion)-25( against)-7( HIV)-25( in)-68( Istanbul\))-11( study)-72( group.)-11( )]TJ
/TT1 1 Tf
0 Tw 0 -1.231 TD
[(Methods:)-17( )]TJ
/TT0 1 Tf
0.03 Tw 4.769 0 Td
[(A)-25( multicentre)-33( observational)-53( retrospective)-45( study)-71( has)-3( been)-7( conducted)-1( by)-21( ACTHIV)-25(-)-52(IST)-59( study)-71( group,)-11( including)-54( 4)-59( centres)]TJ
-4.769 -1.231 Td
[(following)-33(-)-52(up)-42( HIV)-25( patients)-36( in)-68( Istanbul.)-66( Patients)-2( followed)-24(-)-52(up)-42( between)-66( January)-58( 2006)-7(-)-52(June)-63( 2013)-7( were)-64( enrolled)-58( in)-68( this)-59( study.)-24( Age,)]TJ
T*
[(gender,)-70( stage)-16( of)-12( presentation)-35( and)-24( baseline)-45( CD4)-77( cell)-38( counts)-54( upon)-7( diagnosis)-7( were)-64( collected)-54( retrospectively)-16( from the)-71( patients')]TJ
T*
[(files)-68( and)-24( transferred)-11( to)-12( an)-42( HIV)-25( data)-54( base)-63( system.)-17( The)-46( European)-49( definitions)-36( for)-64( late)-3( presentation)-35( and)-24( advanced)-49( HIV)-25( disease)]TJ
T*
[(were)-64( used)-63( in)-68( this)-59( study.)-24( Late)-54( presentation)-35( was)-68( defined)-28( as)-21( presenting)-23( for)-64( care)-55( with)-68( a)-59( CD4+)-31( lymphocyte)-20( counts)-54( below)-3( 350)]TJ
T*
[(cells//mm\263)-60( or)-34( presenting)-23( with)-68( an)-42( AIDS)-51(-)-52(defining)-36( event,)-45( regardless)-24( of)-12( the)-71( cell)-38( count.)-45( )]TJ
/TT1 1 Tf
0 Tw T*
[(Results:)-55( )]TJ
/TT0 1 Tf
0.03 Tw 4.308 0 Td
[(In)-12( total,)-63( 829)-24( naive)-71( patients)-36( were)-64( included)-45( in)-68( this)-59( study.)-24( Seven)-11( hundred)-23( patients)-36( \(82%\))-25( were)-64( males)-25( and)-24( mean)-37( age)-24( was)]TJ
-4.308 -1.231 Td
[(37,51\26111,37)-62( years)-16( \(range)-33( 17)-42(-)-52(79)-42( years\).)-21( Overall,)-16( 441)-24( \(53,2%\))-37( were)-64( late)-3( presenters)-45( and)-24( 252)-24( \(30,4%\))-37( of)-12( these)-15( were)-64( presented)]TJ
T*
[(with)-68( advanced)-49( HIV.)-55( There)-3( was)-68( no)-42( significant)-15( association)-75( between)-66( gender,)-70( condom)-58( usage,)-75( transmission)-3( route)-29( and)-24( stage)-15( of)-12( HIV)]TJ
T*
[(infection.)-75( 74.9%)-11( of)-12( none)-7(-)-52(late)-3( presenters)-45( and)-24( 53.2%)-11( late)-3( presenters)-45( were)-64( diagnosed)-1( by)-21( screening)-50( tests.)-72( The)-46( association)]TJ
T*
[(between)-66( early)-64( diagnosis)-7( and)-24( screening)-50( tests)-42( was)-68( statistically)-12( significant)-16( \(p<)-65( 0.001\).)-41( )]TJ
/TT1 1 Tf
0 Tw T*
[(Conclusion:)-68( )]TJ
/TT0 1 Tf
0.03 Tw 6.154 0 Td
[(The)-46( fraction)-29( of)-12( late)-3( presenters)-45( was)-68( high.)-63( A)-25( substantial)-66( number)-72( of)-12( asymptomatic)-63( HIV)-25( positive)-71( individuals)-24( were)]TJ
-6.154 -1.231 Td
[(identified)-75( by)-21( screening)-50( test,)-33( while)-30( the)-71( diagnosis)-7( of)-12( late)-3( presentation)-35( of)-12( the)-72( disease)-15( was)-68( overall)-55( mostly)-34( based)-45( on)-42( clinical)]TJ
T*
[(symptoms.In)-24( conclusion,)-75( performing)-67( screening)-50( tests)-42( and)-24( supporting)-23( individuals)-24( with)-68( high)-33( risks)-22( to)-12( have)-63( HIV)-25( tests)-42( voluntarily)-37( can)]TJ
T*
[(increase)-67( the)-72( numbers)-33( of)-12( early)-64( diagnosed)-1( patients.)-66( Thus,)-37( spread)-20( of)-12( the)-71( disease)-16( and)-24( treatment)-7( costs)-51( can)-3( be)-42( decreased)-23( by)-21( an)]TJ
T*
[(important)-63( extent.)-75( )]TJ
0 Tw /Span<>> BDC
6.334 0 0 6.334 62.0672 407.2697 Tm
( )Tj
EMC
/TT1 1 Tf
0.03 Tw 8.2342 0 0 8.2342 62.0672 397.7688 Tm
[(Abstract)-21( Details)]TJ
/TT0 1 Tf
0.154 -1.385 Td
[(Abstract)-24( Number:)]TJ
/Span<>> BDC
7.846 0 Td
( )Tj
EMC
0 Tw 3.769 0 Td
(PE21/18)Tj
0.03 Tw -11.615 -1.462 Td
[(Session)-58( Title:)]TJ
/Span<>> BDC
6.154 0 Td
( )Tj
EMC
5.462 0 Td
[(Poster)-33( Session)-58( 1&2)]TJ
-11.615 -2.077 Td
[(Abstract)-24( Category:)]TJ
/Span<>> BDC
8.385 0 Td
( )Tj
EMC
3.231 0.615 Td
[(21.)-71( Epidemiology)-75( \(incl.)-43( HIV)-25(-)-52(Prevalence/Incidence/Dynamics)-4( of)-12( the)-72( HIV)-25(-)-52(Epidemic,)-71( Molecular)]TJ
0 Tw T*
(Epidemiology\))Tj
/Span<>> BDC
6.334 0 0 6.334 62.0672 343.2964 Tm
( )Tj
EMC
ET
endstream
endobj
12 0 obj
<>
endobj
13 0 obj
(_]aV_~)
endobj
21 0 obj
<>stream
Adobe d
'$''''$25552;;;;;;;;;;
%%#(((((#,0000,7;;;7;;;;;;;;;;
%%#(((((#,0000,7;;;7;;;;;;;;;; d "
!1"AQ2STaqB#36Rt
$%&'()*45789:CDEFGHIJUVWXYZbcdefghijrsuvwxyz
!1AQq"2RTa
#$%&'()*3456789:BCDEFGHIJSUVWXYZbcdefghijrstuvwxyz ? B?#n# }B%eK8[9 eR*FSςbrvbLKv8OB2-)uiB8[JIQ`SN )$AY
.B,JɷuIJ c̬eG(o,UTHybrE^"v]JQHuIJ,fiW`p8mvuqjS9F+0v^JTN%kդhP+sl)u,)ćV Cd5-&E$l 31!qPB.(Nc_u
`qX B 32̂qzfVrVuty"RA$`+yC8JlRHoe3pYz:iKL)B~9dgmŶ>*tٱu2*AMYNbZ+2aRZrr]BT:P#"*0e5|Q2z%
Nt9#" JMV2}/P vaP + \(Z I$ 3# MKbB~$
Ⰴa(+
:}-[_ N ^c2l>wPFWc{bkxK:10t.
,TVawd6N F$Z8fVe\ܥ@m E&*Gu3M4[(/1Z-u:L(a)K>3!R^CMR U˂(=s6 )iI6 Mdm\)
QI2'ld1RZZjr]kYR[R; W*II)T `=w,ZTXf̄aWJM6z@8̝TN8o; j(H 2D͌EYDM<F.--y"#0KbR$mme5UWZfbD#ViOKwQW*\SOMl-Ҡx*U14h\#bOiLL6MY@
m{j2l5AiEqcPLe<1td122M٧i.rJت'䜗3h}4fb\QUTd
S"s͂bD"љ)F5Ĕۍ҂Сt$)$p6ԥ@LvmјB5 EsBBBBH BBBBBBBBB +B!B!V!B#INiQ锅ʙmCe˓xV
5 0!rL-ԣ$a
6 &7Ӵii\zZ`'z]z=r r)F]e).qMtŷDijT[Pt/lF29KQ2 %uϞ14Ғ-ʲPZPA((3xZ G"|;zNهeP(qҹqlk1rb+4 :XqN"8
ލ[2HQ͜v\m*Cs -,S%Y¥lmKB%&R,
PA6c9WeqlQjd8)'vnH~=Idݘ}`[XJe )]Y9l`NAj8{v9ʚB┅*!%yF%s
(LIZX(b{rtfK
raE[){Z/ѥf9}\JRëhHr( YtڕJkR9&r ]djPY'uP̥4ŷ*wC,TpEe\wIjm".լm@vFlDyqj֡ˡVÒrtyI)MF
k)ՄAQ9^8eIq j*6Jv19&,i$Իq([8ҢQs}aN2B`R(60Ԭ@qs4IdL#hÃ2AG%EZ*%+p(TJD3qU<-kM;DS!-h Ik &WgZ&JJJK8~VJ)OJIJH.RFBD0&yK@)BEdb,Ulc)L#杔x
,a`Eֻ`NBVH˯νĔ
m cv$%%l'T{i6ófͰQm: ReV@H-*7]uI$\'J"3͊ friXJC4TqĹhrvmL
bR֔bۄ#a
Z)%!S$Ue MӾvh)mUթ4UcHe
"|O!%Kr@:jK}SJ).iBv$(ҏSJlÏq-HXJn!m-`SIr (P(V$N#5-hi/;.HQJJ\ XshTT.4aj
lnR"b%5)O4eZZНT8$6)Mr6RH"-zUА VH.13
eJSέ}йt
)!7xF>@ZT8J1Ĝ